Respuesta :
Answer:
Memo No. 010
New Guinea, August 1, 2020.
Subject: Treatment against Ebola.
From: Alice Creli
To: Roger Ross, Executive Director of Line Med.
Dear Mr Ross.
I am the director of a medical research laboratory in New Guinea. My team and I have devoted our research and resources to finding products that can decrease and control Ebola transmission and infection in West Africa, which consequently improves countless problems facing this region.
I believe that you already know how the transmission of this disease has caused great economic, social and structural wear and tear in the African territory and that although many economic and humanitarian resources have been spent to control this situation, the resources were not efficient, which shows the need for more research and planning, which became more difficult with the arrival of another disease.
In front of that, I would like to communicate that my team has been successful in developing a treatment that has been positive in establishing immunity (against the Ebola virus) in mice. We arrived at this treatment by doing research with DNA from nodulating bacteria and we got promising results, but they need to be tested in humans. We are an independent laboratory and we have few resources to start the second phase of tests and for this reason I write to you, asking for the generous participation of Line Med, in resources for the manufacture of the treatment, as well as help in the dissemination and search for volunteers. I believe that the treatment is promising and could bring many benefits.
Thank you for your time and I await your response.
Kind regards,
Alice Creli
.
Explanation:
A memo is a short, straightforward, simple and clear text that exposes matters quickly and without blurring. Usually this text is related to commercial themes, invitations, or other factors that need a fast and effective communication.
The memo is written with the following points:
- Memo number;
- Sender;
- Recipient, this being mentioned by the position he holds;
- Subject indication;
- Place and date;
- Message body
- Farewell;
- signature
Answer: The Ebola epidemic is still ravaging West Africa, and the death toll has passed 10,000. The labor force and human capital of the economies of the countries affected by Ebola are declining with the increasing number of deaths and people infected with Ebola. The reduction in labor resources caused by the many deaths and the underutilization of human capital caused by the large number of sick people is leading to a decline in output
I have invented an antiviral drug that will cure this deadly disease. The drug is made from a batch of antiviral culture along with minute concentrations of potassium chloride. To produce this drug on large scale, we will need certain capital—sodium chloride, lab equipment, syringes, and oxygen devices to help with breathing. Moreover, we will also need labor in large numbers to act as support and nursing staff who will distribute and administer the drug. The capital needed for this drug is currently used for producing and distributing an antiviral drug for influenza. Considering the urgent need we are facing, I believe that the antiviral drug for the deadly disease Ebola is the need of the hour, and the firm therefore should transfer its resources from producing the flu drug to producing the Ebola antiviral drug. The firm will face a trade-off here, which will lead to a decrease in the production of the flu drug. However, this new drug will certainly improve the condition of those affected by Ebola.
Within a few years, I am sure that the countries that suffered the epidemic will recover their labor. We can soon expect an increase in their production possibilities and a right shift in their PPCs.
Explanation: edmentum